Form 4: Lilly Endowment Sells $48M in Eli Lilly Shares

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 46,606 shares of common stock for approximately $48 million.

Summary

• Lilly Endowment Inc., identified as a 10% owner of Eli Lilly & Co. (LLY), reported transactions on November 13, 2025.
• The reporting person sold a total of 46,606 shares of Eli Lilly & Co. common stock in two separate transactions.
• The first transaction involved the sale of 45,246 shares at a weighted average price of $1,030.21 per share, with prices ranging from $1,030.00 to $1,030.96.
• The second transaction involved the sale of 1,360 shares at a weighted average price of $1,031.777 per share, with prices ranging from $1,031.58 to $1,032.14.
• The total value of the shares sold amounts to approximately $48,015,217.38.
• Following these transactions, Lilly Endowment Inc. beneficially owns 93,060,372 shares of Eli Lilly & Co. common stock.
• The sales were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The filing is a standard Form 4 reporting an insider sale. It does not inherently convey positive or negative sentiment about the company's performance or prospects, as such sales can be for various reasons unrelated to company fundamentals.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports an insider sale by a significant shareholder of a major pharmaceutical company. Such transactions are common for large endowments and can be driven by portfolio rebalancing, diversification strategies, or liquidity needs, rather than specific company-related news. The pharmaceutical industry continues to see significant R&D investment and M&A activity, but this specific filing does not directly relate to those trends.

Related Party Transactions

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., engaged in the sale of common stock. Transactions by 10% owners are considered related party transactions under SEC regulations.

Stakeholder Impact

• Shareholders: May interpret the sale by a significant owner as a signal, though the reasons for the sale are not disclosed in the filing and could be for portfolio management rather than company-specific concerns.
• Investment Professionals: Will note the transaction as part of their analysis of insider activity and ownership changes.

Key Dates

Keywords

Eli Lilly, LLY, Lilly Endowment, Insider Sale, Form 4, Beneficial Ownership, Pharmaceuticals